Comprehensive Approach to DLB Management

Similar documents
Lewy Body Dementia: Diagnosis, Management and Future Directions

Optimizing Clinical Communication in Parkinson s Disease:

Overview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits

Evaluation of Parkinson s Patients and Primary Care Providers

Parkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee

Parkinson s Disease: initial diagnosis, initial treatment & non-motor features. J. Timothy Greenamyre, MD, PhD

The PD You Don t See: Cognitive and Non-motor Symptoms

10th Medicine Review Course st July Prakash Kumar

Parkinson s Disease Initial Clinical and Diagnostic Evaluation. J. Timothy Greenamyre, MD, PhD

Parkinson s Disease Current Treatment Options

Non-Motor Symptoms of Parkinson s Disease

III./3.1. Movement disorders with akinetic rigid symptoms

Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.

The PD You Don t See: Cognitive and Non-motor Symptoms

DIFFERENTIAL DIAGNOSIS SARAH MARRINAN

Revised criteria for the clinical diagnosis of dementia with Lewy. Dementia with Lewy bodies. (Dementia with Lewy Bodies)

475 GERIATRIC PSYCHOPHARMACOLOGY (p.1)

Joint Session with ACOFP and Mayo Clinic. Parkinson's Disease: 5 Pearls. Jay Van Gerpen, MD

Parkinson s Disease in the Elderly A Physicians perspective. Dr John Coyle

Dementia Update. Daniel Drubach, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota

PARKINS ON CENTER. Parkinson s Disease: Diagnosis and Management. Learning Objectives: Recognition of PD OHSU. Disclosure Information

What s new for diagnosing and treating Parkinson s Disease?

Diagnosing and Managing Lewy Body Dementia

Treatment of Parkinson s Disease: Present and Future

Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE

Any interventions, where RCTs in PD are not available, are not included in the tables.

PACIFIC MOVEMENT DISORDERS CENTER AT PACIFIC NEUROSCIENCE INSTITUTE SM

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology

Dementia: It s Not Always Alzheimer s

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology

Parkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s

Key Concepts and Issues in Parkinson s Disease in 2016

The Spectrum of Lewy Body Disease: Dementia with Lewy Bodies and Parkinson's Disease Dementia

Parkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai

Program Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York

Evaluation and Management of Parkinson s Disease in the Older Patient

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.

Welcome and Introductions

What is Parkinson s Disease?

Drug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

United Council for Neurologic Subspecialties Geriatric Neurology Written Examination Content Outline

Depression & Anxiety. What can I do? What are other possible treatments? What is this? Why does this happen? KEY POINTS

Multiple choice questions: ANSWERS

Faculty. Joseph Friedman, MD

Presenter. Dr. Ronald Lucchino

A BRIEF LOOK AT DEMENTIA

2/20/18. History of Parkinson s. What is happening in the brain? DOPAMINE! Epidemiology. Parkinson s Disease. It s much more than tremor

Best Medical Treatments for Parkinson s disease

Parkinson s Disease Update

DRUG TREATMENT OF PARKINSON S DISEASE. Mr. D.Raju, M.pharm, Lecturer

Objectives. Distinguishing Parkinson s disease from other parkinsonian and tremor syndromes. Characteristics. Basal Ganglia Structures

Welcome and Introductions

Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist

Pharmacological Treatments for Neuropsychiatric Symptoms in Dementia 3/22/2018

Prior Authorization with Quantity Limit Program Summary

Appendix N: Research recommendations

Parkinson s Disease. Sirilak yimcharoen

CAREGIVER SUMMIT. The PD You Can't See: Dealing with Non-Motor Symptoms. Kaitlyn Roland, PhD. Sponsored by:

Parkinson s Disease. Prevalence. Mark S. Baron, M.D. Cardinal Features. Clinical Characteristics. Not Just a Movement Disorder

Chapter 20. Media Directory. Amyotrophic Lateral Sclerosis. Alzheimer s Disease. Huntington s Chorea. Multiple Sclerosis

DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future

Dementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada

Psychotropic Medication Use in Dementia

PARKINSON S PRIMER. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada

8/28/2017. Behind the Scenes of Parkinson s Disease

P20.2. Characteristics of different types of dementia and challenges for the clinician

Parkinson s Disease. Patients will ask you. 8/14/2015. Objectives

Alzheimer's disease (AD), also known as Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer s is the most common form of dementia.

Diagnosis and management of non-alzheimer dementias. Melissa Yu, M.D. Department of Neurology

Medications and Non-Pharma Approaches to Treatment. David J. Irwin, MD Penn Frontotemporal Degeneration Center

How to Diagnose Early (Prodromal) Lewy Body Dementia. Ian McKeith MD, FRCPsych, F Med Sci.

FOUNDATION OF UNDERSTANDING PARKINSON S DISEASE

Diagnosis and Treatment of Alzhiemer s Disease

Headway Victoria Epilepsy and Parkinson s Centre

MOVEMENT DISORDERS AND DEMENTIA

Improving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018

ALZHEIMER S DISEASE OVERVIEW. Jeffrey Cummings, MD, ScD Cleveland Clinic Lou Ruvo Center for Brain Health

Parkinson s Disease Associated Sleep Disturbance Ehsan M. Hadi, MD, MPH. Dignity Health Neurological Institute

Cognitive enhancers PINCH ME. Anticholinergic burden BPSD. Agitation, Aggression and antipsychotics

First described by James Parkinson in his classic 1817 monograph, "An Essay on the Shaking Palsy"

Drugs Affecting the Central Nervous System

Parkinson s disease: & related sleep disorders

ASHI691: Why We Fall Apart: The Neuroscience and Neurophysiology of Aging. Dr. Olav E. Krigolson Lecture 5: PARKINSONS DISEASE

Enhanced Primary Care Pathway: Parkinson s Disease

Dementia ALI ABBAS ASGHAR-ALI, MD STAFF PSYCHIATRIST MICHAEL E. DEBAKEY VA MEDICAL CENTER ASSOCIATE PROFESSOR BAYLOR COLLEGE OF MEDICINE

Introduction Lewy body dementia (LBD) is a complex, challenging, and surprisingly

NON-MOTOR SYMPTOMS OF PARKINSON S DISEASE

Dizziness, postural hypotension and postural blackouts: Two cases suggesting multiple system atrophy

John D. Schaeffer, DO PMG Neurology Missoula, MT

10/4/2016. Disclosures. Motor symptoms are Just the tip of the iceberg. Parkinson s Disease for the Primary Care Clinician

With Time, The Pathology of PD Spreads Throughout the Brain

PD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N.

Sleep Dysfunction in Multiple System Atrophy DR CALLUM DUPRE NEUROLOGY/SLEEP MEDICINE CAPITAL HEALTH SYSTEM

Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn

Let s Look at Parkinson s (PD) Sheena Morgan Parkinson s Disease Nurse Specialist Isle of Wight NHS Trust November 2016

PARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease

The Role of Pharmacists in Treating & Managing Parkinson s Disease Author: Mary Jo Carden, RPh, JD Principal, Carden Associates

BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA

Pharmacy Drug Class Review

Transcription:

Comprehensive Approach to DLB Management Bradley F. Boeve, MD Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota

Comprehensive Approach to DLB Management Disclosures Financial Interests/Other Relationships Dr. Boeve currently serves as an investigator for clinical trials sponsored by GE Healthcare and Axovant. He does not receive any personal compensation for his involvement in these trials. He also receives research support from the National Institutes of Health (U01 AG045390, U54 NS092089, P50 AG016574, UO1 AG006786, RO1 AG041797), and the Mangurian Foundation. Off-label and/or Investigational Use Dr. Boeve will discuss the use of several medications that are not FDA-approved for the indications that are reviewed, which include the use of melatonin, clonazepam, cholinesterase inhibitors, carbidopa/levodopa, dopamine agonists, selective serotonin reuptake inhibitors, atypical neuroleptics, anti-amyloid/tau/alphasynuclein immunotherapies, memantine, sedative/hypnotics, and psychostimulants for the management of cognitive impairment, neuropsychiatric disorders, parkinsonism, sleep disorders, and autonomic dysfunction. He may also discuss neuroimaging studies that are not FDA-approved for the indications that are reviewed, which include ioflupane SPECT (DaTscan), FDG-PET, amyloid PET and tau PET imaging in the assessment of patients with cognitive impairment and/or parkinsonism.

Dementia With Lewy Bodies Overview QUESTION: 1. All of the symptoms in DLB reflect problems in the brain. 2. Almost all of symptoms of DLB primarily reflect problems related to the chemical known as dopamine. Which of the following statements is TRUE: 3. The degrees of neuronal death and brain atrophy are greater in DLB compared to Alzheimer s disease. 4. The primary way to manage the problematic symptoms in DLB is to use medications. 5. The diagnosis of DLB is not easy, and the management of DLB is highly complex.

Dementia with Lewy Bodies Overview

Dementia with Lewy Bodies Overview

Dementia With Lewy Bodies Management Cognitive impairment Autonomic dysfunction Consider symptoms as they relate to: Neuropsychiatric features Ask patient/family to prioritize the most troublesome issues they seek to change: 1. 2. 3. Sleep disorders Motor features

QUESTION: Dementia With Lewy Bodies Overview 1. Cholinesterase inhibitors (eg, Aricept, Exelon, Razadyne) Which of the following is LEAST likely to be beneficial for individuals with DLB: 2. Traditional neuroleptics (eg, Haldol) 3. Education + counseling 4. Exercise 5. Melatonin

Dementia With Lewy Bodies Brain-Behavior Relationships A B C A B C

Dementia With Lewy Bodies Brain-Behavior Relationships ABBREVIATIONS Ach HCT DA 5-HT Glu and Gly acetylcholine basal forebrain hypocretin-1 - hypothalamus dopamine substantia nigra serotonin raphe nucleus Neurotransmitters dorsal pons Ach DA 5-HT HCT glutamate (Glu) glycine (Gly)

Dementia With Lewy Bodies Brain-Behavior Relationships COGNITIVE ISSUES A Largely due to reduced Ach Reductions in other brain chemicals contributes to cognitive impairment Some degree of neuron cell loss too A B C HCT B Ach DA 5-HT C

Cognitive impairment Management Varying degrees of memory impairment Dementia With Lewy Bodies Management Verbal blocking Aricept, Razadyne, Exelon Executive dysfunction Bradyphrenia Spatial/geographic disorientation Visual misidentification Fluctuations Education and counseling Therapies: Namenda Sinemet, Mirapex, Neupro Provigil, Nuvigil Methylphenidate, Adderall

Dementia With Lewy Bodies Brain-Behavior Relationships NEUROPSYCHIATRIC ISSUES A Hallucinations and delusions related to DA imbalance Depression related to low 5-HT +/- NE Apathy many causes A B C B Ach DA 5-HT C

Neuropsychiatric features Dementia With Lewy Bodies Management Management Visual hallucinations Illusions Aricept, Razadyne, Exelon Delusions Capgras syndrome Education and counseling Therapies: SSRIs/SNRIs, melatonin Seroquel, Zyprexa Depression Anxiety Agitation/aggressive behavior NO HALDOL Provigil, Nuvigil Methylphenidate, Adderall

Dementia With Lewy Bodies Brain-Behavior Relationships MOTOR ISSUES The Parkinson s disease-like features (parkinsonism) primarily relate to the reduction in DA A A B C B DA C

Motor dysfunction Dementia With Lewy Bodies Management Management Tremor Bradykinesia Rigidity Myoclonus Shuffling gait Stooped posture Difficulty with fine motor skills Masked facies Sialorrhea (drooling) Education and counseling, PT, OT, devices Therapies: Sinemet Mirapex, Requip Neupro patch Clonazepam, Neurontin

Dementia With Lewy Bodies Brain-Behavior Relationships SLEEP ISSUES Daytime sleepiness, insomnia, and fragmented sleep relate in part to the loss in HCT Acting out dreams (RBD) relates to changes in the dorsal pons Reduced DA and 5-HT also affects sleep A A B C HCT B DA 5-HT Glu, Gly C

Sleep disorders Dementia With Lewy Bodies Management Management REM sleep behavior disorder Excessive daytime somnolence Insomnia Obstructive sleep apnea Central sleep apnea Restless legs syndrome Periodic limb movement in sleep Education and counseling Therapies: Clonazepam, Melatonin Provigil, Nuvigil Methylphenidate, Adderall Trazodone, Ambien Chloral hydrate Nasal CPAP Oxygen, Temazepam Mirapex, Sinemet

Dementia With Lewy Bodies Brain-Behavior Relationships AUTONOMIC ISSUES Many autonomic changes related to changes in the spinal cord and peripheral nerves in and around the: nose heart stomach intestines bladder sex organs

Autonomic dysfunction Dementia With Lewy Bodies Management Management Rhinorrhea Orthostatic hypotension Impotence Urinary incontinence Constipation Education and counseling, PT, OT, nonrx measures Therapies: Nasal sprays: Flonase, Atrovent Midodrine, Florinef, salt Viagra, Cialis Enablex, Gelnique, Sanctura Senokot, MiraLAX

Feature AChEI Memantine Cognitive Impairment Neuro-Psychiatric Features Often improves Often improves VH and delusions and apathy Sometimes improves Sometimes improves Dementia With Lewy Bodies Pros and Cons of Medications Atypical Neuroleptics Usually neutral, but can worsen Often improves VH/delusions if dosed appropriately and tolerated SSRIs/SNRIs Dopaminergics Sleep Meds Stimulants Usually neutral Usually Improves depression; Sometimes improves VH and delusions Parkinsonism Rarely worsens Usually neutral Rarely worsens Usually neutral Sleep - daytime alertness Sleep - RBD Often improves Usually neutral Usually neutral Sometimes improves Often worsens hypersomnia Sometimes improves Usually neutral Usually neutral Often worsens VH and delusions Usually improves, but effects modest Sometimes worsens Sometimes worsens Sometimes improves Clonazepam - usually neutral but can worsen Melatonin - sometimes improves VH Usually neutral Can improve alertness by improving sleep continuity Melatonin and Clonazepam usually improve RBD Sometimes improves Sometimes improves VH Usually neutral Often improves Usually neutral Autonomic dysfunction Sometimes improves OH and constipation Usually neutral Often worsens OH and ED Sometimes worsens OH and ED Often worsens OH Usually neutral Can improve OH, but can worsen supine hypertension Legend Greater optimism Modest optimism Caution Greater Caution

Dementia With Lewy Bodies Pros and Cons of Medications Issue/Concern AChEI Memantine Atypical Neuroleptics SSRIs/SNRIs Dopaminergics Sleep Meds Stimulants Clinical Nausea, Diarrhea, Syncope NCS Diabetes, Stroke Orthostatism NCS Orthostatism or syncope NCS Increased BP, Increased HR, Vascular event Laboratory NCS NCS Hyperglycemia, Reduced WBC NCS NCS NCS NCS ECG Bradycardia, Heart block NCS Prolong QT, Arrhythmia Prolong QT, Arrhythmia NCS NCS Tachycardia, Arrhythmia Legend Caution NCS = not clinically significant

Dementia With Lewy Bodies RESOURCES https://www.lbda.org/content/treatment-options

Dementia With Lewy Bodies ACTIVE CLINICAL TRIALS https://www.lbda.org/node/2786

Functioning Dementia With Lewy Bodies FUTURE PROSPECTS REM sleep behavior disorder (RBD) Asymptomatic/minimally symptomatic Prodromal DLB (eg, MCI+RBD) DLB Age

Functioning Dementia With Lewy Bodies FUTURE PROSPECTS REM sleep behavior disorder (RBD) Asymptomatic/minimally symptomatic Prodromal DLB (eg, MCI+RBD) DLB Rx Age

Functioning Dementia With Lewy Bodies FUTURE PROSPECTS REM sleep behavior disorder (RBD) Asymptomatic/minimally symptomatic Prodromal DLB (eg, MCI+RBD) DLB Rx Age

Functioning Dementia With Lewy Bodies FUTURE PROSPECTS REM sleep behavior disorder (RBD) Asymptomatic/minimally symptomatic Prodromal DLB (eg, MCI+RBD) DLB Rx Age

Dementia With Lewy Bodies SUMMARY Issues: Cognitive impairment Neuropsychiatric features Motor features Sleep disorders Autonomic dysfunction Ask patient/family to prioritize the most troublesome issues they seek to change: 1. 2. 3. Optimize management of problematic symptoms and quality of life for patients and their families through education, empowerment, and the use of medication and non-medication approaches